NeuroSense Therapeutics Ltd. Cash And Cash Equivalents
NeuroSense Therapeutics Ltd. (NRSN) had Cash And Cash Equivalents of $2.64 million as of 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Assets › Assets, Current › Cash and Cash Equivalent
ifrs-full:CashAndCashEquivalents · last filed 2024-04-04
- 2023-12-31: Cash And Cash Equivalents $2.64M.
- 2023-06-30: Cash And Cash Equivalents $7.09M.
- 2022-12-31: Cash And Cash Equivalents $3.54M.
- 2022-06-30: Cash And Cash Equivalents $4.35M.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2023-12-31 | $2.64M 20-F · filed 2024-04-04 |
| 2023-06-30 | $7.09M 6-K · filed 2023-08-16 |
| 2022-12-31 | $3.54M 20-F · filed 2024-04-04 |
| 2022-06-30 | $4.35M 6-K · filed 2023-08-16 |
| 2021-12-31 | $11.06M 20-F · filed 2024-04-04 |
| 2021-06-30 | $994.00K 6-K/A · filed 2023-01-19 |
| 2020-12-31 | $699.00K 20-F · filed 2024-04-04 |
| 2019-12-31 | $895.00K 20-F · filed 2023-03-22 |
| 2018-12-31 | $86.00K 20-F · filed 2022-04-14 |